balovaptan   Click here for help

GtoPdb Ligand ID: 10615

Synonyms: compound 1 [PMID: 31951127] | RG7314 | RO5285119
Compound class: Synthetic organic
Comment: Balovaptan ((RG7314, RO5285119) is a potent, selective, orally administered and brain-penetrant vasopressin 1A (V1A) receptor antagonist [2]. It was designed by Hoffmann-La Roche as a treatment for autism spectrum disorder, but its clinical development has been terminated.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 55.55
Molecular weight 409.17
XLogP 6
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1Cc2cc(Cl)ccc2n2c(C1)nnc2C1CCC(CC1)Oc1ccccn1
Isomeric SMILES CN1Cc2cc(Cl)ccc2n2c(C1)nnc2[C@@H]1CC[C@H](CC1)Oc1ccccn1
InChI InChI=1S/C22H24ClN5O/c1-27-13-16-12-17(23)7-10-19(16)28-20(14-27)25-26-22(28)15-5-8-18(9-6-15)29-21-4-2-3-11-24-21/h2-4,7,10-12,15,18H,5-6,8-9,13-14H2,1H3/t15-,18-
InChI Key GMPZPHGHNDMRKL-RZDIXWSQSA-N
No information available.
Summary of Clinical Use Click here for help
Encouraging Phase 2 trial results have been published [1]. Phase 3 evaluation of balovaptan's efficacy will be determined in clinical trial NCT03504917, which began in 2018.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03504917 A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension Phase 3 Interventional Hoffmann-La Roche